REN and diabetes mellitus: Additionally, among two placebo-controlled trials of renin-angiotensin system inhibitor plus thiazide treatment, active treatment reduced all-cause mortality in a trial for patients (mean age 66 years, mean baseline BP 145/81 mm Hg) with diabetes and at least one additional risk factor (ARR 0.26% per year; HR 0.86, 95% CI 0.75 to 0.98) [16] but not in the trial for participants (mean age 66 years, mean baseline BP 138/82 mm Hg) at intermediate risk (ARR 0.02% per year; HR 0.98, 95% CI 0.84 to 1.14) [17].